BRIEF published on 10/05/2026 at 13:17, 1 month 10 days ago ReproNovo nommée parmi les 15 entreprises de biotechnologie les plus prometteuses de 2026 Biotechnologie Santé Des Femmes ReproNovo Fécondité Féroce 15
BRIEF published on 10/05/2026 at 13:17, 1 month 10 days ago ReproNovo Named Among "Fierce 15" Biotech Companies of 2026 Biotechnology Fertility Women's Health ReproNovo Fierce 15
PRESS RELEASE published on 10/05/2026 at 13:12, 1 month 10 days ago FIERCE BIOTECH NAMES REPRONOVO A “FIERCE 15” BIOTECH COMPANY OF 2026 ReproNovo named as one of 2026's Fierce 15 biotechnology companies by Fierce Biotech for innovative therapies targeting male and female infertility and women's health Innovation Biotechnology Fertility ReproNovo Fierce 15
BRIEF published on 07/06/2026 at 07:05, 4 months 9 days ago ReproNovo lance un essai clinique de phase 2 dans l'UE pour son traitement d'implantation d'embryons. ReproNovo RPN-002 Implantation D'embryons Essai Nordique Techniques De Procréation Assistée
BRIEF published on 07/06/2026 at 07:05, 4 months 9 days ago ReproNovo Begins EU Phase 2 Trial for Embryo Implantation Treatment ReproNovo RPN-002 Embryo Implantation NORDIC Trial Assisted Reproductive Technology
PRESS RELEASE published on 07/06/2026 at 07:00, 4 months 9 days ago ReproNovo Announces First Participant Dosed In EU Phase 2 Trial Of RPN-002 Embryo Implantation ReproNovo doses first participant in EU Phase 2 trial of RPN-002 for embryo implantation, aiming to increase IVF success rates with oxytocin receptor antagonist ReproNovo RPN-002 Embryo Implantation EU Phase 2 Trial IVF Success
BRIEF published on 03/20/2026 at 13:05, 7 months 26 days ago ReproNovo Appoints Mark Altmeyer as Chairman of the Board Biopharmaceutical Fertility Leadership ReproNovo Mark Altmeyer
BRIEF published on 03/20/2026 at 13:05, 7 months 26 days ago ReproNovo nomme Mark Altmeyer président du conseil d'administration Biopharmaceutique Direction ReproNovo Mark Altmeyer Fécondité
PRESS RELEASE published on 03/20/2026 at 13:00, 7 months 26 days ago REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD ReproNovo appoints Mark Altmeyer as Chairman of the Board. Altmeyer brings 35+ years of biopharma leadership experience across multiple therapeutic areas Chairman Fertility Biopharma ReproNovo Mark Altmeyer
BRIEF published on 09/30/2025 at 07:05, 1 year 1 month ago ReproNovo obtient l'approbation pour l'essai clinique RPN-001 en Chine Essai Clinique ReproNovo RPN-001 Approbation De La Chine Médecine De La Reproduction
Published on 11/14/2026 at 12:56, 1 day 4 hours ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 1 day 15 hours ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 1 day 16 hours ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 1 day 16 hours ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 1 day 17 hours ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 1 day 17 hours ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 1 day 19 hours ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 1 day 21 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 1 day 22 hours ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 2 days 5 hours ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 2 days 5 hours ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 2 days 9 hours ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 2 days 17 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
